Considering that SIGLEC9 in TAMs has been reported to reduce inflammatory programs and increase the levels of M2-type markers [13], we postulated that aberrant expression of SIGLEC9 is potentially linked to immunosuppressive TME and radioresistance in ESCC. Here, SIGLEC9 is linked to esophageal squamous cell carcinoma.